Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase delta subunit (PDE6D)

The retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase delta subunit (PDE6D), also known as PDE delta subunit, is a small prenyl-binding protein that functions primarily as a soluble transport factor for prenylated proteins, facilitating their shuttling between membranes and targeting to subcellular structures like cilia. In the visual system, it solubilizes the membrane-bound catalytic subunits of rod photoreceptor phosphodiesterase 6 (PDE6αβ), a key enzyme in the phototransduction cascade that hydrolyzes cGMP to regulate light-induced hyperpolarization of photoreceptors. Beyond vision, PDE6D plays a critical role in trafficking farnesyl- or geranylgeranyl-modified small GTPases such as KRAS and HRAS to the plasma membrane, where they become activated to drive cell signaling. Upregulation of PDE6D in cancers like hepatocellular carcinoma correlates with advanced tumor stages, enhanced proliferation, migration, and ERK activation via KRAS enrichment at the membrane, positioning it as an emerging therapeutic vulnerability in KRAS-driven malignancies. Inhibitors targeting PDE6D's prenyl pocket, such as deltarasin and deltaflexin3, disrupt this trafficking to modestly suppress RAS signaling and selectively inhibit growth of PDE6D-dependent, KRAS-mutant cancer cells, with potential synergy alongside approved drugs like sildenafil. Mutations in PDE6D are linked to ciliopathy disorders including Joubert syndrome-22, highlighting its broader role in cellular organization. Ongoing development includes PROTACs for PDE6D degradation, though challenges persist in achieving profound RAS inhibition.

Other names

PDE delta subunitPhotoreceptor cGMP phosphodiesterase delta subunitPDEdelta

Competitive inhibition of prenyl-binding pocket to impair shuttling of prenylated RAS (e.g., KRAS) to plasma membrane, Reduction of RAS membrane enrichment and activation, Heterobifunctional PROTAC-mediated recruitment of E3 ubiquitin ligase for proteasomal degradation of PDE6D, Combination with PKG2 activators (e.g., Sildenafil) to enhance phosphorylation-dependent reduction of KRAS-PDE6D binding